Loading…
Employees: 1,890
Size Chimin Health Management (603222.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $553M, the 3622nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.02 on 6 Nov 2026.
Performance Over six months the shares fell 28.4%, against -10.0% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 0.7% over the last twelve months (peer median +10.8%); the operating margin is -28.2% (peer median 10.6%).
Valuation It trades at 6.8× enterprise value to sales against a peer median of 5.3× (6th most expensive of 18).
Capital Return on invested capital runs 13.4 points below its cost of capital (9.6% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥639M | CN¥684M | CN¥764M | CN¥891M | CN¥833M |
| Revenue growth | — | -10% | -14% | +7% | — |
| Gross profit | CN¥244M | CN¥181M | CN¥245M | CN¥345M | CN¥360M |
| EBITDA | n/a | -CN¥32.8M | CN¥70.3M | CN¥152M | CN¥172M |
| Net income | -CN¥251M | -CN¥246M | -CN¥59.7M | -CN¥65.5M | CN¥34.5M |
| Free cash flow | -CN¥3.20M | -CN¥56.6M | -CN¥47.3M | -CN¥4.97M | CN¥19.2M |
| Capital expenditure | CN¥44.6M | CN¥46.2M | CN¥122M | CN¥149M | CN¥196M |
| Total debt | CN¥807M | CN¥728M | CN¥555M | CN¥509M | CN¥626M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603222.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.8% | -7.8% | 10th lowest of 21 |
| 6-month return | -28.4% | -10.0% | 5th lowest of 21 |
| Distance from 52-week high | -43.2% | -31.5% | 7th lowest of 21 |
| Revenue growth (TTM) | +0.7% | +10.8% | 7th lowest of 20 |
| Operating margin | -28.2% | 10.6% | 3rd lowest of 18 |
| EV / Sales | 6.8× | 5.3× | 6th most expensive of 18 |
| ROIC minus cost of capital | -13.4 pp | -2.6 pp | 5th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |